A detailed history of Verition Fund Management LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 33,530 shares of ALDX stock, worth $161,614. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,530
Previous 219,827 84.75%
Holding current value
$161,614
Previous $727,000 75.24%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.19 - $6.32 $594,287 - $1.18 Million
-186,297 Reduced 84.75%
33,530 $180,000
Q2 2024

Aug 14, 2024

SELL
$3.25 - $4.72 $2.34 Million - $3.4 Million
-720,571 Reduced 76.62%
219,827 $727,000
Q1 2024

May 14, 2024

SELL
$2.77 - $4.22 $1.06 Million - $1.62 Million
-384,436 Reduced 29.02%
940,398 $3.08 Million
Q4 2023

Feb 14, 2024

BUY
$1.47 - $6.06 $572,654 - $2.36 Million
389,561 Added 41.65%
1,324,834 $4.65 Million
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $31,765 - $42,423
5,199 Added 0.56%
935,273 $6.25 Million
Q2 2023

Aug 14, 2023

SELL
$7.11 - $11.89 $4.51 Million - $7.55 Million
-634,954 Reduced 40.57%
930,074 $7.8 Million
Q1 2023

May 15, 2023

BUY
$5.77 - $9.93 $38,693 - $66,590
6,706 Added 0.43%
1,565,028 $15.5 Million
Q4 2022

Feb 14, 2023

SELL
$5.08 - $7.09 $4.29 Million - $5.98 Million
-843,917 Reduced 35.13%
1,558,322 $10.8 Million
Q3 2022

Nov 14, 2022

BUY
$3.8 - $7.74 $1.9 Million - $3.88 Million
501,048 Added 26.35%
2,402,239 $12.8 Million
Q2 2022

Aug 15, 2022

SELL
$2.43 - $4.85 $497,459 - $992,872
-204,716 Reduced 9.72%
1,901,191 $7.59 Million
Q1 2022

May 13, 2022

BUY
$3.25 - $5.17 $2.4 Million - $3.82 Million
739,206 Added 54.09%
2,105,907 $9.36 Million
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $2.51 Million - $6.92 Million
718,494 Added 110.84%
1,366,701 $5.47 Million
Q3 2021

Nov 15, 2021

BUY
$7.94 - $11.31 $955,785 - $1.36 Million
120,376 Added 22.81%
648,207 $5.69 Million
Q2 2021

Aug 16, 2021

BUY
$10.44 - $14.85 $1.16 Million - $1.65 Million
111,114 Added 26.66%
527,831 $5.98 Million
Q1 2021

May 18, 2021

BUY
$6.53 - $14.42 $1.44 Million - $3.17 Million
219,963 Added 111.8%
416,717 $4.95 Million
Q4 2020

Feb 16, 2021

SELL
$6.31 - $8.13 $627,378 - $808,333
-99,426 Reduced 33.57%
196,754 $1.35 Million
Q3 2020

Nov 16, 2020

BUY
$4.0 - $7.53 $1.1 Million - $2.06 Million
274,180 Added 1246.27%
296,180 $2.2 Million
Q2 2020

Aug 14, 2020

BUY
$1.97 - $5.05 $43,340 - $111,100
22,000 New
22,000 $92,000
Q2 2019

Aug 14, 2019

SELL
$6.0 - $9.0 $1.65 Million - $2.48 Million
-275,205 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$7.14 - $9.85 $888,216 - $1.23 Million
124,400 Added 82.49%
275,205 $2.49 Million
Q4 2018

Feb 14, 2019

BUY
$7.26 - $13.29 $1.09 Million - $2 Million
150,805 New
150,805 $1.25 Million

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $281M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.